chrisvoncsefalvay/vaers-outcomes huggingface dataset:
-received vaccine while pregnant: normal pregnancy except for vision loss Feb 2nd -baby born on due date, no complications, healthy weight (6 lbs 15.8 oz) and baby is healthy  SYMPTOMS 3 months post-vaccine, over a 3 week period beginning  4/25/21:   -tingling and "crawling sensation" in arms, legs, left side of head, left ear -extreme headache, fatigue, jerking/convulsions, extreme muscle weakness -ER visit 5/9/21: CT, EKG, labs all normal -fever up to 102F, increased pulse -loss of appetite -numbness in extremities -nerve pain -breast pain -chills and night sweats -pronounced weakness -tongue ulcer -cognitive issues such as brain fog, confusion
Mucous; Headache; shingles on head and forehead; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727), via an unspecified route of administration in the left arm on 26Mar2021 at 11:30 (at the age of 53-years-old), as a single dose for COVID-19 immunisation. Medical history included cyclical neutropenia immune deficiency. The patient did not have any allergies to medications, food or other products. Concomitant medications were not provided. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 29Mar2021 at 12:00, the patient experienced mucous, headache and then shingles on head and forehead. Shingles diagnosed by urgent care. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of shingles which included treatment with antiviral medicine. The clinical outcome of the events mucous, headache and then shingles on head and forehead were not resolved at the time of reporting.   No follow-up attempts are needed. No further information is expected.
Tingling started around her mouth, went up her face, and in her head/tingling lips; Left ear is bothering her; Headache; Felt a rush go through her; This is a spontaneous report from a contactable consumer (patient) received via medical information team. A 68-year-old female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot/Batch number: unknown), via an unspecified route of administration on 16Feb2021 as a single dose for COVID-19 immunization. The patient's medical history included intractable itching. The patient had a reaction to an epidural injection when she had a surgery 25 years ago. The patient's concomitant medications were not reported. On an unspecified date, the patient experienced tingling started around her mouth, went up her face, and in her head/tingling lips, left ear is bothering her, headache, felt a rush go through her. As soon as she had the needle in her arm she felt a rush throughout her arm. She's also experiencing tingling in her mouth, around her lips, head and face. Before putting on her mask her lips start tingling in the outside only. Doesn't know if that should be expected or not. Everyone else she talked to has not had this experience. Tingling is periodic and not constant. Today, her lips are tingling and her left ear is bothering her. She would like to know if this has been reported before and if she should receive the second dose of the vaccine. The clinical outcome of the tingling started around her mouth, went up her face, and in her head/tingling lips, left ear is bothering her, headache, felt a rush go through her were unknown.   No follow-up attempts are Possible. Information on Lot/batch number cannot be obtained.
p/awaking from nap @ 245PM pt started crying for a few mins then seemed to hold breath & gasp-dad noticed perioral cyanosis & periocular cyanosis & paleness of body; also seemed to be shaking arms & legs; seemed to be trembling; groggy
Starting the evening after vaccination patient developed redness and swelling starting about 1&1/2 inches below injection site and expanded to about 5 inches in length and width over the next day.  Patient had fever (99F) for about 24 hours but has resolved.   Redness and swelling still present but has stabilized over the last 8 hours.  Patient took 2 Benadryl the night of 10/13/2020.
This spontaneous report as received from a registered nurse refers to an 18 month old patient. The nurse stated new patient to their office, 8 month old child, has a vaccination record from another health care provider, that shows that ZOSTAVAX (dose, route and lot # not specified) was administered. Nurse stated she thought it might just be a paper documentation error. Additional information is not expected.
On day 2 or 3 she woke up with a rash that wrapped around her neck down the non smallpoxed arm. She had bad abdominal cramps, started with heavy vaginal bleeding outside of her expected menstruation time. She still has cramping. Both arms are very dry and flaky.The emergency dept gave her Benadryl and dx with Vaccinia.
This spontaneous report as received from a registered nurse refers to an unspecified number of patients of unknown age and gender. No pertinent medical history or drug reactions/allergies were provided. The registered nurse reported that improperly stored ROTATEQ was administered to unspecified number of patients, orally (dose and lot number not provided), (dates unspecified). No adverse effects were reported. This case is linked to case MARRS # 1409USA010502 (same reporter link). Additional information is not expected because there was no consent to follow up.
Moderna vaccine was administered outside of facility- reported by patient ? NO LOT NUMBER WERE SUPPLIED ----------------------------------------------------------------------------------------------------------------------- COAGULOPATHY, UNSPECIFIED TYPE 3/13/2022 BRAIN MASS PARTIAL EPILEPSY 2/14/2022 BRAIN MASS ACUTE HYPOXEMIC RESPIRATORY FAILURE 3/13/2022 BRAIN MASS COAGULOPATHY, UNSPECIFIED TYPE 3/13/2022 SECONDARY HYPERCOAGULABLE STATE DUE TO UNSPECIFIED ATRIAL FIBRILLATION PARTIAL EPILEPSY 2/14/2022 SECONDARY HYPERCOAGULABLE STATE DUE TO UNSPECIFIED ATRIAL FIBRILLATION ACUTE HYPOXEMIC RESPIRATORY FAILURE 3/13/2022 SECONDARY HYPERCOAGULABLE STATE DUE TO UNSPECIFIED ATRIAL FIBRILLATION COAGULOPATHY, UNSPECIFIED TYPE 3/13/2022 PNEUMONIA PARTIAL EPILEPSY 2/14/2022 PNEUMONIA ACUTE HYPOXEMIC RESPIRATORY FAILURE 3/13/2022 PNEUMONIA
immed p/vax mom states lt thigh had nodule @ inj site;the nodule persisted for almost 2mo then devel redness & inc warmth @ same site of nodule-2mo p/vax;
Took shot about 3:15pm 12/06/05. Shortly after it hit my heart and my face got hot, My chest hurt the rest of the evening with my heart beating too fast, 12/07/05 3:00pm my chest is still hurting and I did physical work at work an I started panting for breath my hands sweat, got dizzy and hot. My chest still hurts. Additonal term  from Discharge Summary rec'd 12/28/2005: vaccine reaction/sr
Pt presented w/ a large red welt on her deltoid. It was hot and itchy. She was told by PA to use cold compresses.
temperature excursion; This case was reported by a nurse via call center representative and described the occurrence of incorrect storage of drug in a female patient who received HAV (Havrix) (batch number 7HJ74, expiry date 21st August 2022) for prophylaxis.   On 16th August 2021, the patient received Havrix. On an unknown date, unknown after receiving Havrix, the patient experienced incorrect storage of drug. On an unknown date, the outcome of the incorrect storage of drug was unknown.  Additional details were provided are as follows: The patient received Havrix after a temperature excursion (exposed to freezing temperatures at minus 8 degree Celsius for 7 hours and 24 minutes), which led incorrect storage of drug. The reporter consented to follow-up. The case has been linked with case US2021173234, reported by the same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021173234:Same reporter
Pt exp local pain p/inject of Td; 2 days later, redness, swelling, warmth were noted @ the inject site; soreness of the arm persisted;
only got the first dose by day 36; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (only got the first dose by day 36) in a 37-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 01-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Mar-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (only got the first dose by day 36). On 01-Mar-2021, PRODUCT DOSE OMISSION ISSUE (only got the first dose by day 36) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported. No treatment medications were reported.
Breakthrough Case of COVID-19 I had no side effects for the vaccine except for a mild shoulder pain for about 24 hours, then I was fine, I had a mild cough around the 18th of April, which I did not take any medicine for, Pryor to my return from Ireland , on 04/28/2022, I tested positive for COVID-19 but I had not other symptoms but the mild cough, the only reason that I took a test was because it was required for me to do so before I could get on the plane.
Complained of GI upset at 4AM 7/29/04, progressing to vomiting- plans to follow up with PMD. PC to health department to question possibility of Hep B #3 injection and symptom onset.
This case was reported by a other health professional via call center representative and described the occurrence of injection site erythema in a 63-year-old female patient who received SHINGRIX (batch number A4X57, expiry date 13th July 2020) for prophylaxis. On 17th April 2018, the patient received SHINGRIX (subcutaneous). In April 2018, less than a day after receiving SHINGRIX, the patient experienced injection site erythema and injection site swelling. On 17th April 2018, the patient experienced intramuscular formulation administered by other route. On an unknown date, the outcome of the injection site erythema and injection site swelling were recovered/resolved and the outcome of the intramuscular formulation administered by other route was unknown. It was unknown if the reporter considered the injection site erythema and injection site swelling to be related to SHINGRIX. Additional details were reported as follows: The health care professional (HCP) reported that, the patient received the SHINGRIX via subcutaneous route, which led to inappropriate route of vaccination.  The reporter also stated that, within 24 hours the patient experienced redness and swelling at the injection site. The onset of symptoms was within 24 hours and were resolved since then. No additional information was provided.
Moderate pain in injected shoulder, pain was so severe the patient could not shift into 5th gear of manual vehicle. As the evening progressed, patient could not reasonably lift arm initially above shoulder height and then above elbow height. Patient experienced pain that radiated from shoulder to the back of the deltoid. Patient continued to experience pain for 5+ days but continued to decrease every day. Pain was so significant patient could not workout whether lifting weights or running (as running required arm to swing). This was patient's 10th anthrax shot, this reaction was not seen on prior injections.
SLEEP RELATED HYPOVENTILATION DUE TO LOWER AIRWAYS OBSTRUCTION 10/13/2022 CAD (CORONARY ARTERY DISEASE) WO ANGINA  ACUTE DVT OF BILAT LEGS, UNSPECIFIED VEINS 10/14/2022 CAD (CORONARY ARTERY DISEASE) WO ANGINA  ACUTE HYPOXEMIC RESPIRATORY FAILURE 10/14/2022 CAD (CORONARY ARTERY DISEASE) WO ANGINA  RESPIRATORY FAILURE, UNSPECIFIED ACUITY 11/2/2022 CAD (CORONARY ARTERY DISEASE) WO ANGINA  HYPOXIA 10/13/2022 CAD (CORONARY ARTERY DISEASE) WO ANGINA
Information has been received through the pregnancy registry through a nurse concerning a 19 year old female with a history of social smoking, penicillin allergy, and with two previous pregnancies (two elective abortions) who on 01-AUG-2007 was vaccinated intramuscularly with her first dose of Gardasil (Lot # 0469U). There was no concomitant medication. The patient had a blood pregnancy test (date unspecified) which was positive (LMP=13-AUG-2007). The patient sought unspecified medical attention in the office. No symptoms were reported. On 23-OCT-2007 and 30-OCT-2007, the patient had an ultrasound due to elevated beta levels. The ultrasounds showed an empty sac. The reporter indicated that there was a question as to whether there was missed antibodies vs. an ectopic pregnancy, but it was probably missed antibodies. On an unspecified date, the patient had a spontaneous abortion, no further details were provided. Additional information has been requested.
Dry skin; Itchy skin; Injection site warmth; Yeast infection; Injection site redness; This spontaneous case was reported by a consumer and describes the occurrence of DRY SKIN (Dry skin), PRURITUS (Itchy skin), INJECTION SITE WARMTH (Injection site warmth), FUNGAL INFECTION (Yeast infection) and INJECTION SITE ERYTHEMA (Injection site redness) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Psoriatic arthritis and Rheumatoid arthritis.    Concomitant products included COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) for COVID-19 vaccination.   On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) citrate free. On an unknown date, the patient experienced DRY SKIN (Dry skin), PRURITUS (Itchy skin), INJECTION SITE WARMTH (Injection site warmth), FUNGAL INFECTION (Yeast infection) and INJECTION SITE ERYTHEMA (Injection site redness). At the time of the report, DRY SKIN (Dry skin) and PRURITUS (Itchy skin) was resolving and INJECTION SITE WARMTH (Injection site warmth), FUNGAL INFECTION (Yeast infection) and INJECTION SITE ERYTHEMA (Injection site redness) outcome was unknown.            Patient received moderna as a booster dose.  Reporter's causality for the events of dry skin, Itchy skin, Yeast infection, Injection site warmth and injection site redness for humira drug were not reported.  No treatment medications were reported.  It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.
back and knee pain every hour woke up at 0600hrs. my joints were very sore and it was very hard to get out of bed.  it progressed all day and as I went to bed at approximately 22:00hrs. I woke up with severe joint pain almost every hour (knees and back, from my waist to my neck inclusive. as I type this report I am still in severe pain although not as bad.
This spontaneous report was received from a pharmacist refers to one of the two patients of unknown age and gender. Patient medical history and historical conditions were not reported. On 12-SEP-2014, the patient inadvertently administered ZOSTAVAX VIAL single dose, subcutaneous (dose was not reported) (lot # J004599 and expiration date was 18-JUL-2014), that had expired in 18-JUL-2014. Concomitant therapy was not reported. No adverse effects reported. No PQC was involved. The outcome of inadvertently administered ZOSTAVAX VIAL that had expired in 18-JUL-2014 was unknown. The reporter considered inadvertently administered ZOSTAVAX VIAL that had expired in 18-JUL-2014 to be not related to ZOSTAVAX. This case was linked to MARRS# 1409USA008025 (same patient link). Additional information has been requested.
Parsonage-Turner Syndrome; Initial information was received on 09-Dec-2020 regarding an unsolicited valid non-serious case received from a consumer (patient) via other company.  This case involves a male patient who experienced parsonage-turner syndrome (neuralgic amyotrophy), while he received vaccine INFLUENZA VACCINE.  At the time of report, patient was 54 year-old.  Medical history, medical treatment(s), vaccination(s), concomitant medications and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE (produced by unknown manufacturer) [lot number not reported and expiry date not provided] via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date in 1997, the patient developed non-serious parsonage-turner syndrome (neuralgic amyotrophy) (Unknown latency) following the administration of INFLUENZA VACCINE.  The patient could not ever receive influenza or any vaccine that contains the same ingredient and wanted to know if he was eligible to receive the COVID-19 vaccine and was asked to share about co-morbidities and the data.  Details of laboratory data were not reported.  It was not reported if the patient received any corrective treatment.  At the time of report, the outcome of event was unknown.  There will be no information available on batch number for this case.
3RD COVID DOSE GIVEN 11/1/21, MODERNA, #058F21A pt presented to ED with N/V x 3days, diarrhea, poor po intake; tested positive for COVID in ED; O2 supplementation; required intubation; MICU; COVID and bacterial pneumonia; given ABX;  Atrial Fibrillation with RVR; fevers; viral sepsis from COVID being likely cause; renal failure; transitioned to comfort measures; pt passed away in the hospital
Pfizer vaccine was given 1 week after the Moderna vaccine ( 1/14/2021 Lot 011L30A)
Throw up; Dizzy; Black out; High fever. Got medicine to bring fever down and forced to drink Qt of water several times.
Patient developed symptoms the following morning, fever, chills, body aches. He told his neighbor about it and she suggested he lie down and rest. He went to bed and was unable to be reached later in the day. She went to his condo around 7:30 p.m. and found him dead.
covid vaccine breakthrough case  dose 1 Pfizer 1/19/21  EL3249 dose 2 Pfizer 2/9/21 EM9810 dose 3 Pfizer 9/25/21 301308A
Patient described burning upon injection of Pneumovax.  Patient contacted us the following day, on September 11, 2022 to let us know he was concerned about swelling and pain in his right arm.  He described only being able to lift his arm to 90 degrees, suffered insomnia due to pain throughout the night, warmth in the area, and swelling approximately 2 inches larger circumference of arm.  He described that this started shortly after getting vaccines.  I advised the patient to seek medical attention if he thought it was necessary but the symptoms sounded like normal side effects.  The patient stated that the injections were not given near the shoulder joint.  I also recommended an ice pack at the area to reduce swelling and discomfort.  The patient opted to wait 24 hours and follow up with us to let us know how he was doing.  He did contact us again on September 12th and stated that although his arm was now red, the swelling had gone down, his mobility had improved and he felt he was going to be fine.
Since receiving the COVID-19 vaccine, patient has been sleeping 20 hours a day with decreased oral intake. On 1/30, his mobility began decreasing and he was no longer able to use the walker he normally uses. He is also usually alert and oriented x 4, altered (including hallucinations) when admitted to the ICU on 2/1/21. Also with hypertension and AKI.  Management: precedex for agitation, labetalol for hypertension, fluids and foley for AKI
Hey Pfizer, you can stuff your newest money making Covid medication up your ass along with your ineffective and mislabeled vaccine; Hey Pfizer, you can stuff your newest money making Covid medication up your ass along with your ineffective and mislabeled vaccine; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP), Program ID: (RA). The reporter is the patient.  A patient (no qualifiers provided) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported.  The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant), outcome "unknown" and all described as "Hey Pfizer, you can stuff your newest money making Covid medication up your ass along with your ineffective and mislabeled vaccine".  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
I had palpitations and they would come and go and then I kept having them like panic attacks and I had some labs and it was thyroid autoimmune but I never had those symptoms before I had them the day of the vaccine the 15 minutes that I had to wait their I started having palpitations in the clinic and they had me wait their for an hour but I still keep on having panic attacks since I had tha vaccine
asthma; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 73-year-old female patient received BNT162b2 (BNT162B2), on 01Feb2021 as dose 2, single (Lot number: EL9262) at the age of 73 years for covid-19 immunisation. The patient's relevant medical history included: "Asthma" (ongoing), notes: She says she has a history of asthma, she has had it all her life, but hadn't been to the hospital for it for the last 25 years. The patient's concomitant medications were not reported. Vaccination history included: BNT162b2 (Dose 1, LOT: EL3246), administration date: 12Jan2021, when the patient was 73-year-old, for Covid-19 Immunization. The following information was reported: ASTHMA (hospitalization) with onset Feb2021, outcome "not recovered". The patient was hospitalized for asthma (start date: Feb2021, hospitalization duration: 7 day(s)). The event "asthma" required physician office visit. The patient underwent the following laboratory tests and procedures: Blood glucose: 462.  No follow-up attempts are possible. No further information is expected.
I hate to be one of these people. But, I dont smoke, drink, do drugs and live a healthy active lifestyle.   Cancer does not run in my family and I am not exposed to paint or chemicals.   I was diagnosed with high grade t1 kidney and bladder cancer in July 2022. Symptoms started around May. Last June I did get a kidney stone which is rare for me as well. Again, not a crazy blame vaccine person but this seems very odd.
Last half of August 2004 my 9 year old daughter developed 2-3 small red blisters on her lower back and was experiencing a lot of pain. 5 days later on that Friday her whole thigh are was covered with a red rash and hundreds of blisters. Two days after the full breakout on Sunday she developed small blisters on her stomach and back, next day on Monday I took her back. She had a slight case of the chicken pox. Her doctor and another were confused by that. She was given Acyclovir 5 a day for 10 days. She fulled recovered within 3 weeks from the onset. Now on 4/4/05 she developed 3 small blisters and started complaining about her knee hurting, next day complained of sharp pains in her left thigh area. Took her to doctors Thurs 4/7 it was the start of another shingles out break. She is currently on Acyclovir again.
pt recv vax 25MAR96 & 24hr p/vax pt exp light headedness & dizziness to the point of passing out;BP was nl & pulse was 100-105;approx 1/2 hr later exp palpitations w/an uneasy feeling;
8/23/2023 - 8/30/2023 (7 days) Date of Admission: 8/23/2023  Discharge Date: 08/30/2023 Discharge Disposition: Home or Self Care  past medical history of SLE, recent left lower extremity DVT with splenic infarct and discharged on 07/03/2023 on Eliquis, recent COVID-19 1 week prior to arrival, presented with worsening left upper quadrant pain over the past 1 week prior to arrival. Patient asymptomatic from this regard.  No hypoxia or pneumonia noted.  Continue supportive care.   2/22/2022 Janssen  1855194